Dreyling M et al. TRIANGLE: autologous transplantation after a rituximab/ibrutinib/ara-c containing induction in generalized mantel cell lymphoma – a randomized European mcl network trial. ASH 2022;Abstract 1.

Wang ML et al. Targeting BTK with ibrutinib in relapsed or refractory mantel-cell lymphoma. N Engl J Med 2013;369(6):507-16. Abstract

Wang ML et al. Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab and rituximab maintenance as a first-line treatment for older patients with mantle cell lymphoma. ASCO 2022;Abstract LBA7502.

Wang ML et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022 Jun 30;386(26):2482-94. Abstract

Wang ML et al. Acalbrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY0004): A single-arm, multicentre, phase 2 trial. Lancet 2018;391(10121):659-67. Abstract

Wang ML et al. Safety and efficacy of acalabrutinib plus venetoclax in rituximab in patients with treatment-naïve mantle cell lymphoma. ASH 2021;Abstract 2416.

Wang ML et al. Pirtobrutinib, a next generation, highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase ½ BRUIN study. ASH 2021;Abstract 381.

Wang ML et al. Pirtobrutinib in covalent bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol 2023;JCO2300562. Abstract